Pfizer and Sangamo re-open PhIII of hemophilia A gene therapy; AEON headed to PhIII
A year after voluntarily pausing the Phase III study of their hemophilia A gene therapy program, and four months after FDA lifted the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
